Top Page
Rocket Doctor AI
(AIDR)
Rocket Doctor AI (AIDR) vs. iShares MSCI Canada ETF (EWC)
Rocket Doctor AI Business Overview & Revenue Model
Rocket Doctor AI Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.75K | 10.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 468.15K | 10.99K | 0.00 | -377.28K | -656.40K | -326.85K |
| EBITDA | -8.73M | -7.52M | -2.33M | 0.00 | 0.00 | 0.00 |
| Net Income | -8.75M | -7.55M | -3.72M | -3.80M | -13.86M | -2.91M |
Balance Sheet | ||||||
| Total Assets | 18.54M | 1.28M | 739.31K | 13.67K | 942.51K | 313.20K |
| Cash, Cash Equivalents and Short-Term Investments | 117.59K | 1.23M | 715.53K | 2.50K | 916.75K | 312.64K |
| Total Debt | 613.46K | 152.00K | 584.79K | 566.28K | 0.00 | 0.00 |
| Total Liabilities | 10.45M | 486.43K | 1.48M | 2.20M | 832.62K | 576.46K |
| Stockholders Equity | 8.09M | 792.77K | -738.05K | -2.19M | 109.90K | -263.26K |
Cash Flow | ||||||
| Free Cash Flow | -5.08M | -4.44M | -740.08K | -1.46M | -6.29M | -2.01M |
| Operating Cash Flow | -5.08M | -4.44M | -740.08K | -1.46M | -6.29M | -2.01M |
| Investing Cash Flow | -1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 5.60M | 4.97M | 1.45M | 540.62K | 6.94M | 1.86M |
Rocket Doctor AI Technical Analysis
Rocket Doctor AI Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$517.04M | 159.66 | 1.45% | ― | 59.34% | -23.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$35.52M | -6.18 | ― | ― | -48.53% | -9.66% | |
48 Neutral | $62.88M | -4.24 | -207.53% | ― | ― | 7.04% | |
46 Neutral | C$1.03M | -3.38 | -40.64% | ― | -100.00% | 65.85% | |
44 Neutral | C$12.09M | -2.43 | ― | ― | ― | 48.94% | |
33 Underperform | C$7.64M | -4.83 | ― | ― | ― | -67.11% |
Rocket Doctor AI Corporate Events
Rocket Doctor AI has signed a new in-network agreement with a major commercial insurer in California, extending digital access to its network of board-certified physicians to approximately 175,000 additional members and lifting its total in-network reach to more than 13 million covered lives across key U.S. markets. The deal deepens the company’s presence in one of the country’s largest healthcare markets, strengthens its payer mix across employer-sponsored plans, and is expected to support sustained revenue growth as employers and health plans increasingly seek digital-first, clinician-led care solutions that improve access and reduce friction for members, including those in underserved and remote communities.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.79 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI Inc. has closed a non-brokered private placement of 7,428,571 units at C$0.70 per unit, raising approximately C$5.2 million, with each unit comprising one common share and one warrant exercisable at C$0.85 until January 22, 2027. Completed under the listed issuer financing exemption, the offering involves freely tradable securities in Canada, included finder commissions and warrants, and will fund digital marketing and customer acquisition, operating and administrative costs, research and development and general working capital, supporting the company’s efforts to scale operations and accelerate its U.S. growth strategy while reinforcing its position in the competitive AI-driven digital health space.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.76 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI Inc., a physician-led medical AI and digital health platform provider, has increased the size of its previously announced non-brokered private placement under the listed issuer financing exemption to a maximum of $5.2 million in gross proceeds, with units priced at $0.70, reflecting strong investor demand. The company has filed an amended and restated offering document on SEDAR+ and its own website to reflect the upsize, a move that is expected to bolster its capital position as it advances its AI-driven clinical decision-support tools and virtual care marketplace, potentially strengthening its competitive footing in technology-enabled healthcare and supporting expansion into underserved markets.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.78 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI Inc. has increased the size of its previously announced non-brokered private placement under the listed issuer financing exemption to a maximum of $4.5 million in gross proceeds, with units priced at $0.70 each, citing strong investor demand while keeping all other terms of the offering unchanged. The upsized financing underscores growing market interest in the company’s AI-powered healthcare technology and is expected to bolster its capacity to scale its digital health platforms and decision support systems, potentially strengthening its competitive position in virtual care and expanding its reach into underserved markets in Canada and the U.S.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.78 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI Inc. has granted a total of 75,000 stock options, exercisable at $0.74 per share for three years, and 212,148 restricted share units, also with a three-year term, to its consultants under existing share compensation plans, with all awards vesting over one year. The equity-based incentives are aimed at aligning consultant interests with the company’s long-term growth in AI-driven healthcare, supporting Rocket Doctor AI’s efforts to scale its physician-focused decision support tools and virtual care platforms in key North American markets and reinforcing its positioning as a technology provider targeting efficiency and access in underserved healthcare segments.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.73 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI has completed the acquisition of Alea Health Holdings, adding therapist-led mental health capabilities and complementary clinical workflow and decision-support technology to its AI-driven digital health platform. The all-share-and-cash deal, which includes assumption of a limited SAFE-related obligation but no long-term liabilities, will see Alea’s team and technology integrated into Rocket Doctor AI’s product roadmap, bolstering its physician-led marketplace and strengthening its strategic position in virtual care by enhancing clinical efficiency, care consistency and patient outcomes for North American patients, especially in underserved and remote regions.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.73 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI Inc. has launched a non-brokered private placement under Canada’s listed issuer financing exemption to raise a minimum of approximately $3 million through the sale of 4,285,715 units at $0.70 each, with each unit comprising one common share and a one-year warrant exercisable at $0.85. The financing, which may include finder’s fees and additional warrants, is expected to close around January 19, 2026, subject to minimum subscription and regulatory approvals, and the company plans to deploy the proceeds toward digital marketing and customer acquisition, operating and administrative costs, research and development, and general working capital, supporting its growth ambitions in AI-powered healthcare and expansion of its digital platform for physicians and patients.
The most recent analyst rating on (TSE:AIDR) stock is a Hold with a C$0.71 price target. To see the full list of analyst forecasts on Rocket Doctor AI stock, see the TSE:AIDR Stock Forecast page.
Rocket Doctor AI has partnered with the CAN Health Network and Health Cities to launch an AI-powered Clinical Decision Support System (CDSS) in Alberta. The initiative, set to begin in December 2025, will initially be implemented at four primary care sites, aiming to reduce intake time and improve diagnostic accuracy. This project addresses critical challenges in Alberta’s healthcare system, such as staffing shortages and limited access to care, by providing AI-driven tools to improve efficiency and patient access. The collaboration underscores Rocket Doctor AI’s commitment to modernizing healthcare through responsible AI innovation, with plans for a province-wide rollout in 2026.
Rocket Doctor AI Inc. has announced a change in its executive team, with Christopher Cherry stepping in as the Interim Chief Financial Officer, replacing David Worner. The company has also granted stock options and restricted share units to its executive officers, directors, and consultants, which are part of its share compensation plans. This move is part of Rocket Doctor AI’s strategy to strengthen its leadership and incentivize its team, potentially impacting its operational efficiency and market positioning.
Rocket Doctor AI Inc., through its digital health platform Rocket Doctor, has announced a strategic partnership with Toronto Metropolitan University (TMU) to enhance clinical education for medical learners in Canada. This collaboration aims to expand teaching capacity by connecting independent physicians with TMU’s medical school, facilitating clinical faculty appointments, and supporting learner observation and mentorship. The partnership is poised to strengthen Ontario’s healthcare workforce by integrating diverse care settings, including virtual care, and preparing future physicians to meet the evolving needs of the healthcare system.
Rocket Doctor AI reported strong momentum in Q3 2025, driven by its U.S. expansion, new payer contracts, and platform growth. The company achieved continued revenue growth despite seasonal challenges and improved its cash position with a successful capital raise. Notably, Rocket Doctor expanded its in-network reach to over 13 million U.S. members, positioning itself for accelerated growth in the U.S. market. The company also launched initiatives like the Healthy Aging Program and emergency department diversion in Canada, reflecting its commitment to addressing healthcare challenges.
Rocket Doctor AI has entered into a definitive agreement to acquire Alea Health Holdings Ltd., aiming to enhance its capabilities in AI-driven mental health solutions. The acquisition will integrate Alea’s advanced online therapy platform with Rocket Doctor AI’s Global Library of Medicine, expanding its mental health services and geographic reach, particularly into the Middle East. This move is expected to strengthen Rocket Doctor AI’s position in the healthtech industry by leveraging Alea’s expertise and presence in high-growth markets, while also enhancing its mental health and primary care integration.
Rocket Doctor AI Inc. has announced the appointment of four senior leaders to its U.S. operations as part of a strategic initiative to accelerate growth and expand its digital health platform across key states. This move aims to strengthen the company’s medical and commercial capabilities, enhance clinical operations, and support its expansion efforts, particularly in rural and underserved communities, thereby advancing its vision for a more equitable healthcare system.